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ABSTRACT  
The objective of the  present  study  was  to  prepare  and  evaluate  microspheres  for  the controlled release of Zidovudine from the prepared 
microspheres using different polymers. The microspheres were prepared by ionic gelation method. The prepared microspheres were 
characterized for FTIR, scanning electron microscopy (SEM), the percentage drug content, entrapment efficiency, and in vitro dissolution 
studies. Accelerated stability studies were also carried out for the formulations. The microspheres were spherical in shape and free flowing. The 
entrapment efficiency was varying from 76 to 86%. The release of drug  from  the  microspheres was extended up to  8  to  12  hours. FTIR 
studies showed the stable character of Zidovudine in the microspheres. SEM studies revealed that the microspheres were  porous  in  nature.  
The release kinetics studies revealed that the prepared microspheres were best  fitted  to  the  zero  order for all eight formulations and peppa’s 
model. The release kinetics data and characterization studies indicated that the drug release from microspheres was diffusion – controlled and 
the microspheres were stable in nature. 
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Acquired Immunodeficiency Syndrome (AIDS), which is now 
a plague in several countries, was first identified in California 
in 1981. According to data published in the December, 2003 
AIDS Epidemic Update, [1] an estimated 40 million people 
were living with HIV/AIDS at the end of 2003, of whom as 
many as 70% are living in Sub-Saharan Africa. In addition, an 
estimated 3 million people died of HIV/AIDS during 2003, of 
whom as many as 80% were living in sub- Saharan Africa. 
The World Health Organization (WHO) estimates that 
HIV/AIDS caused 2% of all deaths and 6% of deaths due 
to infectious diseases in India in 1998. If current HIV/ 
AIDS policies continue, by 2033 AIDS will account for an 
estimated 17 percent of all deaths and 40 percent of deaths 
from infectious disease. Following the launch of generic 
antiretroviral drugs by Indian pharmaceutical companies in 
2000 and the decline in the costs of these  drugs,  an  
increasing number of people with HIV/AIDS have been -
using antiretroviral therapy. Of the estimated 550,000 
people with AIDS in India, 370,000 reside in 60 major cities. 
Physicians in these cities are treating 90,000 of these people, 
11,700 of whom (8,700 males and 3,000 females) are 
receiving antiretroviral therapy [2]. In such a way the 
antiretroviral therapy play essential      role in the 
management of AIDS patients. 
Zidovudine is a synthetic nucleoside analog that is being 
increasingly used as the core of an antiretroviral regimen for 
the treatment of HIV infection. Zidovudine, the (-)-
enantiomer of 2′, 3′-dideoxy-3′-thiacytidine, is a nucleoside 
analog that inhibits HIV reverse transcriptase. [3] In vivo, 
nucleoside analogs are phosphorylated intracellularly by 
endogenous kinases to putatively active 5′- triphosphate 
(3TC-TP) derivatives that prevent HIV replication by 
competitively inhibiting viral reverse transcriptase and 
terminating pro viral DNA chain extension. [4,5] Zidovudine 
is rapidly absorbed after oral administration with an 
absolute bioavailability of 86% ± 16%, peak serum 
concentration of Zidovudine (Cmax) of 1.5 ± 0.5 mcg/mL  
and  mean  elimination half-life (t½) of 5 to 7 hours, thus 
necessitating frequent administration to maintain constant 
therapeutic drug levels. [6]Therefore, the objective of the 
present work is paying attention to provide a long acting 
pharmaceutical formulation containing Zidovudine in  a  
modified release matrix as microspheres, to maintain the 
blood levels of the active ingredient for a prolonged period of 
time [7]. 
MATERIALS AND METHODS 
Materials 
Zidovudine was obtained as a gift sample from Milton Labs, 
Pondicherry. HPMC, Chitosan, Sodium Carboxyl methyl 
cellulose was Gift sample from novel drugs, Trichy. Sodium 
Alginate, Calcium Chloride, bought from S.D Fine chemicals, 
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Mumbai. All the chemicals and reagents used in the study 
were of analytical grade. 
Preparation of microspheres 
The microspheres were prepared by the ionotropic gelation 
technique. The sodium alginate solution was prepared by 
dispersing the sodium alginate in de-ionized water under 
continuous stirring for 30 minutes. The weighed amount of 
the drug was thoroughly mixed with sodium alginate 
dispersion. By following the same procedure the alginate 
beads of different ratios  of drug: polymer were prepared. 
The resulted homogeneous dispersion was extruded in to 
the 5% calcium chloride solution through hypodermic 
syringe with flat tip needle (20G)  and stirred for  15 
minutes at 100rpm using magnetic stirrer. The formed micro 
beads were allowed to cure for   30 minutes in the calcium 
chloride solution to complete the gelation reaction. The 
microspheres were then filtered and dried in hot air oven at 
60ºC for 3 hr [8, 9, 16, 18, 19]. 
CHARACTERIZATION OF MICROSPHERES 
FTIR study 
The Zidovudine microspheres were subjected to FT-IR 
analysis by the following method [23], an approximately 
minimum quantity (less than 4mg) of sample was 
thoroughly blended  with  adequate quantity of IR  grade KBr 
(less than 100mg) in mortar.  The mix was then made into   
KBr pellets by hydraulic compression lever.   The samples 
were the analyzed in a double beam    IR spectrometer using 
KBr film as negative control (blank). 
Scanning electron microscopy 
Morphological details of the specimens were determined by 
using a scanning  electron  microscope (SEM). 
Granulometric studies 
Particle size distribution pattern was determined by sieve 
analysis on mechanical sieve shaker  [16, 20], using different 
meshes (12, 16, 20 and 30) of American society of testing 
materials. 
Micrometric properties of the beads 
The mean particle size of the alginate microspheres was 
determined by  optical  microscopic  method using a pre-
calibrated stage micrometer [10]. 
Flow properties of Beads 
The flow properties of prepared microspheres were 
investigated by measuring the Angle of Repose by using 
fixed funnel method [17]. Depends upon these values, the 
flow properties of the microspheres can be assumed. The 
Angle of Repose Values was mentioned in the Table-3. The 
value of angle of repose was calculated by using the 
following formula, 
Angle of repose (θ) = tan -1 h/r 
h=cone height, r=radius of circular base formed by the 
microspheres on the ground. The bulk and tapped densities 
were measured in a 10ml graduated cylinder as a measure of 
packability of the microspheres. Each experiment was 
carried out in triplicate. Results were shown in Table-3 
Drug content (mg) 
100 mg microspheres were powdered and transferred into a 
100 ml volumetric flask  and  the volume was made upto the 
mark with 6.8 pH phosphate buffer and kept aside for 12 hrs 
with occasional shaking. Then the absorbance was analyzed 
spectrophotometrically at 270 nm. Three determinations 
were carried out for each formulation. The drug content was 
calculated by using the formula; 
Drug content = concentration × dil factor × conversion factor 
× amt. of stock sol. 
Drug entrapment efficiency 
Zidovudine content in the microspheres was estimated by a 
UV-spectrophotometric method [10, 11]. Accurately 
weighed 100mg of microspheres (100 mg) were powdered 
and suspended in 6.8   pH phosphate buffer. The resulting 
solution was kept for 24hrs. Next day it was stirred for 
20min using ultra sonicator. The solution was filtered 
through a 0.45 µm membrane filter, after suitable dilution, 
Zidovudine content in the filtrate was analysed at 270nm 
using UV-Visible spectrophotometer. The obtained 
absorbance was plotted on the standard curve to get the 
exact concentration of the entrapped drug. Calculating this 
concentration with dilution factor the percentage of actual 
drug encapsulated in microspheres was calculated. The drug 
entrapment efficiency was determined using following 
relationship 
The yield was calculated. 
          Actual drug content 
Percentage yield =------------------------------------⤫100 
  Theoretical drug content 
In Vitro Drug Release Studies 
In vitro dissolution studies were performed by using USP 
type I dissolution apparatus at 75 rpm [7]. The microspheres 
were weighed and filled in the empty capsule shells and  
placed  in  the basket. The dissolution medium (900ml) 
consisted of 0.1M hydrochloric acid for the first 2 hours and 
then changed to phosphate buffer pH 7.4 from 2nd to 10th 
hour. The temperature was maintained at 37°C ± 5°C. An 
aliquot (5 mL) was withdrawn at specific time intervals and 
replenished with an equivalent volume of dissolution fluid. 
Drug content was determined by UV– visible 
spectrophotometer at 270 nm. 
Kinetics of drug release 
The suitability of several equations to identify the 
mechanisms for the release of drug was tested with respect 
to the release data, and it was found that up to 50% of drug 
was released. The drug release data of the in-vitro 
dissolution study was analyzed with various kinetic 
equations like zero-order [12] (% release v/s time), 
firstorder [13] (Log % retained v/s time), Higuchi model 
[14] and korsmeyer and peppas equation [15]. Coefficient of 
correlation (r) values were  calculated for the linear curves 
obtained by regression analysis of the above plots. 
The value of ‘n’ gives an indication of the release mechanism; 
when n = 1, the release rate is independent of time (zero-
order) (case II transport), n = 0.5 for Fickian diffusion and 
when 0.5 <  n <1.0, diffusion and non-Fickian transport are 
implicated. Lastly, when n > 1.0 super case II transport is 
apparent. K values are release rate constants according to 
the models considered; R2 values are determination 
Coefficients; and n is the exponent of the korsmeyer-peppas 
model. 
Determination of stability of the microspheres 
The microspheres prepared in the present study were filled 
in the hard gelatin capsules and stored   in HDPE containers 
at 40°C/75% RH for 3 months as per ICH guidelines [22]. 
The samples were then characterized for % drug content. 
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RESULTS AND DISCUSSION 
Preparation of microspheres 
Microspheres of Zidovudine were prepared (eight 
formulations) by ionotropic gelation technique and the 
formulations were evaluated for different parameters. The 
compositions of the alginate micro beads were given in the 
Table-1.
 
TABLE-1: The compositions of the alginate micro beads 
















F1 3% 5% _ _ _ 1% 
F2 4% 5% _ _ _ 1% 
F3 3% 5% _ 0.5% _ 1% 
F4 3% 6% _ 1% _ 1% 
F5 3% 5% _ _ 0.5% 1% 
F6 3% 6% _ _ 1% 1% 
F7 3% 5% 0.5% _ _ 1% 
F8 3% 6% 1% _ _ 1% 
 
Characterization of microspheres 
Granulometric studies 
In the granulometric study, it was observed from the table that about 65 – 81 percent of microspheres were of 16 mesh size, 
which proves the flexibility of the method. The  size  distribution of microparticles was reported in Table-2. 
Table - 2: Granulometric Study 
Formulation code #12 (1.68 mm) 
1190-1680µm 
#16 (1.19 mm) 
840-1190µm 
#20 (0.84 mm) 
590-840 µm 
#30 (0.59 mm) 
297-590 µm 
F-1 16.19±0.415 6.54±0.310 8.25±0.215 4.89±0.185 
F-2 14.77±2.193 8.15±0.102 9.22±0.526 3.78±0.456 
F-3 15.95±0.826 9.25±0.427 7.21±0.264 2.85±0.156 
F-4 19.85±0.152 11.92±0.670 6.84±0.816 3.52±0.156 
F-5 24.01±0.810 9.15±0.536 6.23±0.011 2.05±0.188 
F-6 27.55±0.311 10.88±0.115 7.14±0.483 3.71±0.882 
F-7 20.22±0.402 9.01±0.045 5.88±0.151 2.85±0.456 
F-8 24.25±0.692 10.25±0.340 6.10±0.484 2.93±0.185 
Values are mean±SD, n=3. 
 
In this prepared Zidovudine microspheres, with the increase  
in  HPMC  percentage  the  distribution of particle size shifts 
to the higher sieve size due to  increase  in  the  internal  
viscosity of the medium. 
Micrometric properties of the beads 
Zidovudine containing microspheres were in the size range 
of  0.77±0.76  to  0.98±0.94. Zidovudine -loading amount, 
stirring speed, curing time, polymer concentration and 
cross- linking agent seemed to affect the values of particle 
size. The results were shown in table No.3. 
Flow properties of Beads 
The flow property of the microspheres was checked by using 
the angle of repose method. Acceptable range of angel of 
repose was found to be 24 – 31˚. All the formulations angle 
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Table - 3: flow property, entrapment efficiency, mean diameter of particle of microspheres 
FORMULATION CODE ANGLE OF REPOSE ENTRAPMENT EFFICIENCY DRUG 
CONTENT 
MEAN DIAMETER OF 
PARTICLE (mm) 
F1 31º.20' ±0.11 82.14±0.59 11.65±0.12 0.79±0.02 
F2 28º.20'±0.17 89.60±0.16 11.96±0.58 0.77±0.12 
F3 25 º.10'±0.22 90.19±0.86 12.01±0.28 0.97±0.02 
F4 24 º.30'±0.25 86.16±0.15 13.25±0.35 0.98±0.08 
F5 26 º.60'±0.28 91.61±0.22 12.22±0.62 0.86±0.18 
F6 24 º30'±0.54 94.67±0.54 13.45±0.48 0.89±0.38 
F7 24º30'±0.21 90.10±0.34 12.94±0.25 0.85±0.65 
F8 26 º30'±0.57 92.23±0.28 14.22±0.12 0.93±0.28 
Values are mean± SD, n=3. 
 
Drug entrapment efficiency & Drug content 
The drug content of prepared formulations was found to be 
in the range of 89.15 – 98.47%. The drug entrapment 
efficiency of all the formulations was in the range of 82.14– 
94.67. The results   of the each formulation drug entrapment 
efficiency values were shown in Table No: 03. Drug 
entrapment efficiency of microspheres values of the different 
formulations were observed and reported, as increases the 
concentration of sodium alginate and hydroxyl propyl 
methyl cellulose automatically drug entrapment efficiency 
also increases and drug content ranges from 11.65 to 
14.22 mg were shown in table-3. 
In Vitro Drug Release Studies 
The In-Vitro drug release studies of the different 
formulations cumulative percentage drug release was 
observed in the range of 84.63– 97.17. The release studies 
were conducted in triplicate and the results were shown in 
Table 4 and in Figure-1. The formulations F1, F2 containing 
1, 2% sodium alginate respectively showed a release of 
96.12, 94.15% after 10 hours. This shows that more 
sustained release was observed with the increase in 
percentage of sodium alginate. The formulations F3, F4 
containing 3% sodium alginate and 0.5, 1% sodium carboxy 
methyl cellulose showed 88.12, 86.17 % drug release 
respectively. The formulations F5, F6 containing 3% sodium 
alginate and 0.5, 1% hydroxyl propyl  methyl  cellulose 
showed a release of 97.17, 94.01% after 10 hours. Finally the 
formulations F7, F8 containing 3% sodium alginate and 0.5, 
1% Chitosan showed a release of 97.17, 94.01% after 10 
hours.
 
Table - 4: In-Vitro Dissolution Profile for Formulation F1 TO F8 
Time 
(hrs) 
% Drug Release 
F1 F2 F3 F4 F5 F6 F7 F8 
1 3.42±0.04 3.32±0.122 3.54±0.06 3.11±0.09 3.55±0.02 3.32±0.012 3.55±0.13 2.92±0.15 
2 4.92±0.12 4.24±0.02 3.85±0.16 3.22±0.05 4.24±0.05 3.96±0.021 4.77±0.09 3.23±0.05 
3 25.55±0.08 27.15±0.78 22.55±0.08 20.55±0.22 23.95±0.07 28.56±0.04 23.25±0.12 19.77±0.06 
4 38.97±0.12 36.84±0.12 37.32±0.07 35.67±0.12 41.27±0.12 36.84±0.18 33.85±0.22 34.52±0.20 
6 56.22±0.17 55.13±0.06 57.14±0.09 53.25±0.21 62.45±0.10 58.25±0.11 55.22±0.11 51.11±0.17 
8 87.39±0.23 79.17±0.46 84.55±0.12 77.85±0.05 86.36±0.15 82.57±0.18 82.78±0.15 75.78±0.02 
10 96.12±0.51 94.15±0.08 88.12±0.115 86.17±0.01 97.17±0.15 94.29±0.01 86.22±0.18 84.63±0.12 
Values are mean± SD, n=3 
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Figure 1: In-Vitro Drug Release of All Eight Formulations 
 
Maximum release of Zidovudine from the various 
formulations was achieved in 12 hrs or longer, Figure1.   
Formulation   F8   showed   sustained   drug   release,   when    
compared    to    all   other formulations. 
Kinetics of drug release 
According to results obtained, the ‘n’ value Korsmeyer- 
Peppas equation was in range of 0.910    to 0.905 which 
suggest the drug release from mixture of polymers and Na 
cmc containing Microspheres were non-fickian diffusion 
mechanism. Similarly ‘n’ value for hydroxyl propyl methyl 
cellulose was in range of 0.917 to 0.904 which suggests the 
drug release was non-fickian diffusion mechanism; similarly 
‘n’ value for chitosan was in range of 0.935 to 0.912 which 
suggests the drug release was non-fickian diffusion 
mechanism super case II transport evidenced with diffusion 
exponent values (n). 
In vitro release data proved that formulation F8 having 1% 
Sodium alginate and 1% chitosan as polymers showed more 
optimum sustained release profile with maximum 
entrapment efficiency followed by zero-order kinetics. The 
release kinetics was shown in Table-5. 
The values of diffusion co-efficient ranged between n=1.557 
and 1.666 indicating  the  drug release from the 
microspheres followed the anomalous transport and super 
case-II transport mechanism controlled by swelling and 
relaxation of polymer chains. 
 
Table-5: Drug Release Kinetics Data 
Formulation Zero 
order 
First order Korsermayer-Peppa’s 
 R  R r N  
F1  0.978  0.781 0.934 1.599 
F2  0.984  0.867 0.915 1.603 
F3  0.967  0.841 0.910 1.609 
F4  0.976  0.872 0.905 1.657 
F5  0.976  0.835 0.917 1.628 
F6  0.978  0.893 0.904 1.626 
F7  0.970  0.935 0.935 1.557 
F8  0.979  0.853 0.912 1..666 
 
Determination of stability of the microspheres 
The stability of microspheres was determined. The samples 
were then characterized for % drug content and from the 
results it can be observed that there was no significant 
change in the % drug content of the formulations [22]. The 
results were summarized in Table-6. 
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Table- 6: results of assay for formulations F-1 to F-8 after accelerated stability studies. 
 
Days 
% Drug Release, 40ºc 
F1 F2 F3 F4 F5 F6 F7 F8 
1 95.16±0.01 92.24±0.10 94.34±0.08 95.46±0.12 92.13±0.81 97.12±0.15 97.22±0.12 98.46±0.05 
4 94.50±0.09 93.23±0.01 97.16±0.15 96.14±0.15 95.12±0.15 98.52±0.07 95.16±0.05 96.14±0.18 
17 93.50±0.10 92.65±0.12 96.85±0.88 95.85±0.47 94.26±0.45 95.26±0.07 93.85±0.08 95.55±0.14 
21 93.23±0.12 92.25±0.54 96.25±0.76 95.54±0.05 93.62±0.18 94.64±0.08 93.25±0.07 95.14±0.18 
38 92.89±0.01 91.73±0.18 95.75±0.07 93.57±0.18 91.28±0.15 93.82±0.04 92.75±0.48 93.57±0.17 
45 92.54±0.11 91.25±0.78 95.21±0.16 90.15±0.78 89.52±0.13 91.82±0.18 91.21±0.18 92.15±0.08 
 
Scanning electron microscopy 
Values are mean±SD, n=3.
Morphological details of the specimens were determined by using a scanning  electron  microscope (SEM). The morphology of 
the microspheres was shown in Figure 2.  Scanning  electron microscopy (SEM) results (Figure 2) show that the microspheres 
were spherical and that the microspheres prepared with Chitosan had a formed smooth surface. 
 
FIGURE 2: SCANNING ELECTRON MICROGRAPHS OF Zidovudine MICROSPHERES 1(a), 1(b), AND 1(c) FORMULATIONS 
F3, F6, F7 
FTIR study 
The FTIR study revealed that the scanning range was 400-4000cm-1, resolution was 4cm-1.  Spectra of the Zidovudine, and the 
drug with sodium alginate were  obtained and  compared  for the compatibility. FTIR studies indicates four bands present in the 
Zidovudine spectrum, namely; N-H, O-H, C=O, C=N linkages respectively. The same bands were also found in the spectra of   the 
formulations, showing that no drug-polymer interaction occurred. The figure clearly shows  that there was no significant 
compatibility between the drug and polymer used for the  preparations. The FTIR graphs are shown in Figure 3 and 4.
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FIGURE 3: FTIR FOR PURE DRUG, SODIUM ALGINATE, HPMC AND NA CMC 
 
FIGURE 4: FTIR FOR PURE DRUG, SODIUM ALGINATE AND CHITOSAN 
 
CONCLUSION 
In the present study an attempt was made to prepare 
Zidovudine microspheres by using Ionotropic gelation 
technique. The method was successfully used for 
preparation of microspheres using  sodium alginate and 
with other coating polymers like Chitosan, Na CMC, HPMC,  
as  drug  release  modifiers.  The  Zidovudine   drug   release   
from   microspheres   formulated   with  sodium alginate 
with 1% Chitosan as coating polymer showed a satisfactory 
sustained release profile. As the formulation F8 was  the  
best  formulation  based  on  better  controlled  release  and  
good  entrapment  efficiency.  High  entrapment  efficiency  
was  observed  in  the microspheres prepared with 
combination of sodium alginate and Chitosan. The results of  
accelerated stability study on the microspheres revealed 
that the formulations were stable.  The  study further 
supported  with  FTIR  study  for  absence  of  compatibility  
with  drug  and polymer. The results proved that the 
Zidovudine microspheres can be best alternate for 
conventional tablets for HIV patients’ treatment. 
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